Jack Bowden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jack Bowden has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- George Davey Smith
University of Bristol
21 shared publications - Qingyuan Zhao
Statistical Laboratory, University of Cambridge
8 shared publications - Frank Dudbridge
University of Leicester
6 shared publications - Gibran Hemani
University of Bristol
6 shared publications - Luke C. Pilling
University of Exeter
6 shared publications - Martin K. Rutter
University of Manchester
6 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 67
Genetics identifies obesity as a shared risk factor for co-occurring multiple long-term conditions
Background Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an increasingly important clinical problem, but little is known about the underlying causes. We investigate the role of a critical multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared genetics amongst 71 common LTCs. Methods In a population of northern Europeans, we estimated genetic correlation, between LTCs and partial genetic correlations after adjustment for the genetics of BMI. We used multiple causal inference methods to confirm that BMI causally affects individual LTCs, and their co-occurrence. Finally, we quantified the population-level impact of intervening and lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Results BMI partially explains some of the shared genetics for 740 LTC pairs (30% of all pairs considered). For a further 161 LTC pairs, the genetic similarity between the LTCs was entirely accounted for by BMI genetics. This list included diabetes and osteoarthritis and gout and osteoarthritis: Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset of these pairs, and therefore BMI-lowering interventions would likely reduce their prevalence. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently have both LTCs. Conclusions Our genetics-centred approach quantifies the contribution of obesity to multimorbidity. Our method for calculating full and partial genetic correlations is published as an R package {partialLDSC}. 1234567890():,; 1234567890():,;
- 4 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 67
Open AccessGenetics identifies obesity as a shared risk factor for co-occurring multiple long-term conditions
Background Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an increasingly important clinical problem, but little is known about the underlying causes. We investigate the role of a critical multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared genetics amongst 71 common LTCs. Methods In a population of northern Europeans, we estimated genetic correlation, between LTCs and partial genetic correlations after adjustment for the genetics of BMI. We used multiple causal inference methods to confirm that BMI causally affects individual LTCs, and their co-occurrence. Finally, we quantified the population-level impact of intervening and lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Results BMI partially explains some of the shared genetics for 740 LTC pairs (30% of all pairs considered). For a further 161 LTC pairs, the genetic similarity between the LTCs was entirely accounted for by BMI genetics. This list included diabetes and osteoarthritis and gout and osteoarthritis: Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset of these pairs, and therefore BMI-lowering interventions would likely reduce their prevalence. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently have both LTCs. Conclusions Our genetics-centred approach quantifies the contribution of obesity to multimorbidity. Our method for calculating full and partial genetic correlations is published as an R package {partialLDSC}. 1234567890():,; 1234567890():,;
- Open Access
- 30 December 2025
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 21 (12) , e1011967
Getting to GRIPS with MR-Egger: Modelling directional pleiotropy independently of allele coding
Mendelian Randomisation Egger regression (MR-Egger) is a popular method for causal inference using single-nucleotide polymorphisms (SNPs) as instrumental variables. It allows all SNPs to have direct pleiotropic effects on the outcome, provided that those effects are independent of the effects on the exposure, known as the InSIDE assumption. However, the results of MR-Egger, and the InSIDE assumption itself, are sensitive to which allele is coded as the effect allele for each SNP. A pragmatic convention is to code the alleles with positive effects on the exposure, which has some advantages in interpretation but some statistical limitations. Here we show that if the InSIDE assumption holds under all-positive coding of the exposure effects, it cannot hold under all-positive coding of the pleiotropic effects, and argue that this undermines the soundness of MR-Egger. We propose a modification that has the Genotype Recoding Invariance Property (GRIP), achieving the main aim of MR-Egger without the difficulties of allele coding. Our approach, MR-GRIP, is valid under a “Variance Independent of Covariance Explained” assumption (VICE), which amounts to an inverse relationship between exposure effects and pleiotropic effects. Examples and simulations suggest that MR-GRIP can reconcile differences between MR-Egger and alternative methods.
- 30 December 2025
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 21 (12) , e1011967
Open AccessGetting to GRIPS with MR-Egger: Modelling directional pleiotropy independently of allele coding
Mendelian Randomisation Egger regression (MR-Egger) is a popular method for causal inference using single-nucleotide polymorphisms (SNPs) as instrumental variables. It allows all SNPs to have direct pleiotropic effects on the outcome, provided that those effects are independent of the effects on the exposure, known as the InSIDE assumption. However, the results of MR-Egger, and the InSIDE assumption itself, are sensitive to which allele is coded as the effect allele for each SNP. A pragmatic convention is to code the alleles with positive effects on the exposure, which has some advantages in interpretation but some statistical limitations. Here we show that if the InSIDE assumption holds under all-positive coding of the exposure effects, it cannot hold under all-positive coding of the pleiotropic effects, and argue that this undermines the soundness of MR-Egger. We propose a modification that has the Genotype Recoding Invariance Property (GRIP), achieving the main aim of MR-Egger without the difficulties of allele coding. Our approach, MR-GRIP, is valid under a “Variance Independent of Covariance Explained” assumption (VICE), which amounts to an inverse relationship between exposure effects and pleiotropic effects. Examples and simulations suggest that MR-GRIP can reconcile differences between MR-Egger and alternative methods.
- Open Access
- 2 August 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (11) , 1-12
Clinical utility of self-reported sleep duration and insomnia symptoms in type 2 diabetes prediction
Aims/hypothesis: Suboptimal sleep health is linked to higher risks for incident type 2 diabetes. We aimed to assess the clinical utility of adding self-reported sleep traits to a type 2 diabetes prediction model. Methods: In this cohort study, we used UK Biobank data and Cox proportional hazards models to examine how self-reported sleep duration and insomnia symptoms were associated with incident type 2 diabetes risk. Harrell’s C statistic and net reclassification improvement (NRI) were used to assess whether sleep traits improved the incident type 2 diabetes discrimination and predictive utility achieved using QDiabetes variables, with and without including a type 2 diabetes polygenic risk score (PGS). Independent replication was explored in the Nurses’ Health Study, the Nurses’ Health Study II and the Health Professionals Follow-up Study. Results: Extremes of sleep duration and occasional or frequent insomnia symptoms were associated with higher risks for incident type 2 diabetes. In the UK Biobank and replication cohorts, adding sleep traits to the QDiabetes risk score did not improve type 2 diabetes prediction (C statistic: QDiabetes alone 0.8933; QDiabetes + sleep duration 0.8939; QDiabetes + insomnia 0.8931; QDiabetes + sleep traits 0.8935). The corresponding total NRI values were: 0.08 (95% CI −0.18, 0.33), 0.04 (95% CI −0.08, 0.16) and 0.04 (95% CI −0.10, 0.18). Inclusion of PGS data marginally improved the type 2 diabetes risk prediction achieved using The QDiabetes calculator, with or without the inclusion of sleep traits in the model (QDiabetes + PGS: C statistic 0.8945; total NRI 0.20 [95% CI 0.12, 0.28]; QDiabetes + PGS + sleep traits: C statistic 0.8946; total NRI 0.18 [95% CI 0.09, 0.27]). Conclusions/interpretation: While sleep duration and insomnia symptoms were associated with type 2 diabetes risk, they are not useful for improving type 2 diabetes prediction beyond QDiabetes model performance. Inclusion of a type 2 diabetes PGS marginally improved prediction but lacked clear clinical utility. Graphical
- 2 August 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (11) , 1-12
Open AccessClinical utility of self-reported sleep duration and insomnia symptoms in type 2 diabetes prediction
Aims/hypothesis: Suboptimal sleep health is linked to higher risks for incident type 2 diabetes. We aimed to assess the clinical utility of adding self-reported sleep traits to a type 2 diabetes prediction model. Methods: In this cohort study, we used UK Biobank data and Cox proportional hazards models to examine how self-reported sleep duration and insomnia symptoms were associated with incident type 2 diabetes risk. Harrell’s C statistic and net reclassification improvement (NRI) were used to assess whether sleep traits improved the incident type 2 diabetes discrimination and predictive utility achieved using QDiabetes variables, with and without including a type 2 diabetes polygenic risk score (PGS). Independent replication was explored in the Nurses’ Health Study, the Nurses’ Health Study II and the Health Professionals Follow-up Study. Results: Extremes of sleep duration and occasional or frequent insomnia symptoms were associated with higher risks for incident type 2 diabetes. In the UK Biobank and replication cohorts, adding sleep traits to the QDiabetes risk score did not improve type 2 diabetes prediction (C statistic: QDiabetes alone 0.8933; QDiabetes + sleep duration 0.8939; QDiabetes + insomnia 0.8931; QDiabetes + sleep traits 0.8935). The corresponding total NRI values were: 0.08 (95% CI −0.18, 0.33), 0.04 (95% CI −0.08, 0.16) and 0.04 (95% CI −0.10, 0.18). Inclusion of PGS data marginally improved the type 2 diabetes risk prediction achieved using The QDiabetes calculator, with or without the inclusion of sleep traits in the model (QDiabetes + PGS: C statistic 0.8945; total NRI 0.20 [95% CI 0.12, 0.28]; QDiabetes + PGS + sleep traits: C statistic 0.8946; total NRI 0.18 [95% CI 0.09, 0.27]). Conclusions/interpretation: While sleep duration and insomnia symptoms were associated with type 2 diabetes risk, they are not useful for improving type 2 diabetes prediction beyond QDiabetes model performance. Inclusion of a type 2 diabetes PGS marginally improved prediction but lacked clear clinical utility. Graphical
- Open Access
- 22 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-15
Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Background: Statins are prescribed to lower LDL cholesterol. Clinical guidelines recommend 30–50% reduction within 3 months, yet many patients do not achieve this. We investigated predictors of LDL-c reduction, treatment adherence, and adverse clinical outcomes in a sample of UK Biobank participants. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median = 16 days prior, IQR = 28) and within a year of starting treatment (median = 89 days, IQR = 125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within 1 year of statin initiation, genetic factors, post-treatment LDL-c reduction, and clinical adverse outcomes. For 13,000 patients with ≥ 3 LDL-c measures, we used inverse probability of treatment weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: LDL-c reduction following statin initiation was predicted by time until the 1st measurement (up to 26% greater reduction if returned ≤ 3 months vs > 3 months), PDC (up to 38% reduction when PDC > 95% [high] vs. 15% when PDC < 50% [low]), and the pharmacogenetic variant SLCO1B1*5 (lowest reduction in CC-allele: 37% versus TT-allele: 39.5%). Longitudinal causal modelling showed that the most recent PDC measure exerted the largest influence on overall LDL-c reduction, followed by the initial PDC. Genetic predictors of reduced PDC included liability to schizophrenia (Coeftop 20% − 1.94, 95%CI − 2.69 to − 1.19), while genetic liability to cardiovascular diseases increased PDC (Coeftop 20%1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09–1.54) and cataract (HR 1.20, 95%CI 1.07–1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73–0.84). Conclusions: We identify substantial variability in the time to first on-treatment LDL-c measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL-c monitoring, and statin adherence. We show its subsequent impact on long-term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimize treatment efficacy, safety, and long-term clinical outcomes.
- 22 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-15
Open AccessUnderstanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Background: Statins are prescribed to lower LDL cholesterol. Clinical guidelines recommend 30–50% reduction within 3 months, yet many patients do not achieve this. We investigated predictors of LDL-c reduction, treatment adherence, and adverse clinical outcomes in a sample of UK Biobank participants. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median = 16 days prior, IQR = 28) and within a year of starting treatment (median = 89 days, IQR = 125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within 1 year of statin initiation, genetic factors, post-treatment LDL-c reduction, and clinical adverse outcomes. For 13,000 patients with ≥ 3 LDL-c measures, we used inverse probability of treatment weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: LDL-c reduction following statin initiation was predicted by time until the 1st measurement (up to 26% greater reduction if returned ≤ 3 months vs > 3 months), PDC (up to 38% reduction when PDC > 95% [high] vs. 15% when PDC < 50% [low]), and the pharmacogenetic variant SLCO1B1*5 (lowest reduction in CC-allele: 37% versus TT-allele: 39.5%). Longitudinal causal modelling showed that the most recent PDC measure exerted the largest influence on overall LDL-c reduction, followed by the initial PDC. Genetic predictors of reduced PDC included liability to schizophrenia (Coeftop 20% − 1.94, 95%CI − 2.69 to − 1.19), while genetic liability to cardiovascular diseases increased PDC (Coeftop 20%1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09–1.54) and cataract (HR 1.20, 95%CI 1.07–1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73–0.84). Conclusions: We identify substantial variability in the time to first on-treatment LDL-c measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL-c monitoring, and statin adherence. We show its subsequent impact on long-term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimize treatment efficacy, safety, and long-term clinical outcomes.
- Open Access
Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Background: Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: Predictors of LDL-c reduction following statin initiation included the time until the 1 st measurement, PDC, and the pharmacogenetic variant SLCO1B1 *5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDCtop 20% -1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coef top 20% 1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84). Conclusion: We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.
Open AccessUnderstanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
Background: Statins are commonly prescribed to lower LDL cholesterol. Clinical guidelines recommend 30-50% reduction within 3 months, yet many patients do not achieve this. We investigated the impact of patient characteristics and genetics on LDL-c reduction, treatment adherence, and adverse clinical outcomes. Methods: We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median=16 days prior, IQR=28) and within a year of starting treatment (median=89 days, IQR=125). Adherence was defined as the “proportion of days covered” (PDC). We estimated associations between PDC within one year of statin initiation, genetic factors, post-treatment LDL reduction, and clinical adverse outcomes. For 13,000 patients with ≥3 LDL-c measures, we used inverse probability weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally. Results: Predictors of LDL-c reduction following statin initiation included the time until the 1 st measurement, PDC, and the pharmacogenetic variant SLCO1B1 *5. LDL-c reduction was greater in those with high adherence versus lower adherence (38% reduction when PDC>95% [high] vs. 15% when PDCtop 20% -1.94, 95%CI -2.69 to -1.19), whilst genetic liability to cardiovascular diseases increased PDC (Coef top 20% 1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09-1.54) and cataract (HR 1.20, 95%CI 1.07-1.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73-0.84). Conclusion: We identify substantial variability in the time to first on-treatment LDL measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL monitoring and statin adherence. We show its subsequent impact on long term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimise treatment efficacy, safety, and long-term clinical outcomes.
- Open Access
- 16 December 2024
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 20 (12) , e1011506
Estimating and visualising multivariable Mendelian randomization analyses within a radial framework
Background: Mendelian randomization (MR) is a statistical approach using genetic variants as instrumental variables to estimate causal effects of a single exposure on an outcome. Multivariable MR (MVMR) extends this to estimate the direct effect of multiple exposures simulatiously. MR and MVMR can be biased by the presence of pleiotropic genetic variants in the set used as instrumental variables, violating one of the core IV assumptions. Genetic variants that give outlying estimates are often considered to be potentially pleiotropic variants. Radial plots can be used in MR to help identify these variants. Analogous plots for MVMR have so far been unavailable due to the multidimensional nature of the analysis. Methods: We propose a radial formulation of MVMR, and an adapted Galbraith radial plot, which allows for the estimated effect of each exposure within an MVMR analysis to be visualised. Radial MVMR additionally includes an option for removal of outlying SNPs which may violate one or more assumptions of MVMR. A RMVMR R package is presented as accompanying software for implementing the methods described. Results: We demonstrate the effectiveness of the radial MVMR approach through simulations and applied analyses. We highlight how outliers with respect to all exposures can be visualised and removed through Radial MVMR. We present simulations that illustrate how outlier removal decreases the bias in estimated effects under various forms of pleiotropy. We apply Radial MVMR to estimate the effect of lipid fractions on coronary heart disease (CHD). In combination with simulated examples, we highlight how important features of MVMR analyses can be explored using a range of tools incorporated within the RMVMR R package. Conclusions: Radial MVMR effectively visualises causal effect estimates, and provides valuable diagnostic information with respect to the underlying assumptions of MVMR.
- 16 December 2024
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 20 (12) , e1011506
Open AccessEstimating and visualising multivariable Mendelian randomization analyses within a radial framework
Background: Mendelian randomization (MR) is a statistical approach using genetic variants as instrumental variables to estimate causal effects of a single exposure on an outcome. Multivariable MR (MVMR) extends this to estimate the direct effect of multiple exposures simulatiously. MR and MVMR can be biased by the presence of pleiotropic genetic variants in the set used as instrumental variables, violating one of the core IV assumptions. Genetic variants that give outlying estimates are often considered to be potentially pleiotropic variants. Radial plots can be used in MR to help identify these variants. Analogous plots for MVMR have so far been unavailable due to the multidimensional nature of the analysis. Methods: We propose a radial formulation of MVMR, and an adapted Galbraith radial plot, which allows for the estimated effect of each exposure within an MVMR analysis to be visualised. Radial MVMR additionally includes an option for removal of outlying SNPs which may violate one or more assumptions of MVMR. A RMVMR R package is presented as accompanying software for implementing the methods described. Results: We demonstrate the effectiveness of the radial MVMR approach through simulations and applied analyses. We highlight how outliers with respect to all exposures can be visualised and removed through Radial MVMR. We present simulations that illustrate how outlier removal decreases the bias in estimated effects under various forms of pleiotropy. We apply Radial MVMR to estimate the effect of lipid fractions on coronary heart disease (CHD). In combination with simulated examples, we highlight how important features of MVMR analyses can be explored using a range of tools incorporated within the RMVMR R package. Conclusions: Radial MVMR effectively visualises causal effect estimates, and provides valuable diagnostic information with respect to the underlying assumptions of MVMR.
- Open Access
Increased risk of asthma in female night shift workers
Background Asthma is more common in females and more common in night shift workers. Since increasing numbers of females are becoming shift workers it is important to determine if shift work-associated asthma risk is higher in females. Research Question Is increasing frequency of night shift work more strongly related to prevalent asthma in females than in males? Study Design and Methods We used cross-sectional data from >280,000 UK Biobank participants and logistic regression models adjusted for demographic and lifestyle factors to describe sex differences in prevalent asthma related to shift work frequency. To obtain mechanistic insights, we explored associations with chronotype, sex hormones and menopause. Results Compared to female day workers, female permanent night shift workers had higher covariate-adjusted odds of moderate-severe asthma (OR: 1.50 (95% CI 1.18 – 1.91)) but there was no corresponding relationship in males (OR 0.95 (95% CI 0.72 – 1.26); sex interaction p-value = 0.01). Similar relationships were observed for ‘all asthma’ and for ‘wheeze or whistling in the chest’ outcomes. Female shift work-related asthma was driven by relationships in postmenopausal women not using HRT (e.g., adjusted OR: 1.89 (1.24-2.87) for moderate-severe asthma; sex interaction p-value = 0.02 in permanent nightshift workers compared to dayworkers) but these relationships attenuated to the null in postmenopausal women using HRT. Interpretation Our finding that increasing shift work frequency is more strongly related to asthma in females than in males could have Public Health implications. Intervention studies should determine if modifying shift work schedules or HRT can reduce asthma risk in females.
Open AccessIncreased risk of asthma in female night shift workers
Background Asthma is more common in females and more common in night shift workers. Since increasing numbers of females are becoming shift workers it is important to determine if shift work-associated asthma risk is higher in females. Research Question Is increasing frequency of night shift work more strongly related to prevalent asthma in females than in males? Study Design and Methods We used cross-sectional data from >280,000 UK Biobank participants and logistic regression models adjusted for demographic and lifestyle factors to describe sex differences in prevalent asthma related to shift work frequency. To obtain mechanistic insights, we explored associations with chronotype, sex hormones and menopause. Results Compared to female day workers, female permanent night shift workers had higher covariate-adjusted odds of moderate-severe asthma (OR: 1.50 (95% CI 1.18 – 1.91)) but there was no corresponding relationship in males (OR 0.95 (95% CI 0.72 – 1.26); sex interaction p-value = 0.01). Similar relationships were observed for ‘all asthma’ and for ‘wheeze or whistling in the chest’ outcomes. Female shift work-related asthma was driven by relationships in postmenopausal women not using HRT (e.g., adjusted OR: 1.89 (1.24-2.87) for moderate-severe asthma; sex interaction p-value = 0.02 in permanent nightshift workers compared to dayworkers) but these relationships attenuated to the null in postmenopausal women using HRT. Interpretation Our finding that increasing shift work frequency is more strongly related to asthma in females than in males could have Public Health implications. Intervention studies should determine if modifying shift work schedules or HRT can reduce asthma risk in females.
- Open Access
Genetics identifies obesity as a shared risk factor for co-occurring multiple long-term conditions
Background: Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an increasingly important clinical problem, but often little is known about the underlying causes. Observational studies are highly susceptible to confounding and bias, and patients with multiple LTCs are usually excluded from randomised controlled trials. We investigate the role of a potentially critical multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared genetics amongst 71 common LTCs. Methods and Findings: In a population of northern Europeans, we estimated unadjusted pairwisegenetic correlation, , between LTCs and partial genetic correlations after adjustment for the genetics of BMI, . We compared these correlations using a bespoke block-jackknife approach to assess whether differences between the estimates were statistically meaningful. We then used multiple causal inference methods to confirm that BMI causally affects not only individual LTCs, but also their co-occurrence. Finally, we attempted to quantify the population-level impact of intervening and lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Our results showed evidence that BMI partially explains some of the shared genetics for 740 LTC-pairs (30% of all pairs considered). For a further 161 LTC-pairs, the genetic similarity between the LTCs was entirely accounted for by BMI genetics. This list included diabetes and osteoarthritis: , as well as those involving LTCs from the same broad family, or ‘domain’, such as gout and osteoarthritis: . Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset of these pairs, and therefore BMI-lowering interventions would reduce the prevalence of these pairs of LTCs. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently have both LTCs. Conclusions: Our genetics-centred approach shows that obesity is an important mechanistic cause of many shared long-term conditions. We identify LTC pairs for which obesity is the predominating shared risk factor, and cases where it is one of the several shared risk factors involved. Our method for calculating full and partial genetic correlations is published as an R package {partialLDSC} for use by the research community.
Open AccessGenetics identifies obesity as a shared risk factor for co-occurring multiple long-term conditions
Background: Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an increasingly important clinical problem, but often little is known about the underlying causes. Observational studies are highly susceptible to confounding and bias, and patients with multiple LTCs are usually excluded from randomised controlled trials. We investigate the role of a potentially critical multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared genetics amongst 71 common LTCs. Methods and Findings: In a population of northern Europeans, we estimated unadjusted pairwisegenetic correlation, , between LTCs and partial genetic correlations after adjustment for the genetics of BMI, . We compared these correlations using a bespoke block-jackknife approach to assess whether differences between the estimates were statistically meaningful. We then used multiple causal inference methods to confirm that BMI causally affects not only individual LTCs, but also their co-occurrence. Finally, we attempted to quantify the population-level impact of intervening and lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Our results showed evidence that BMI partially explains some of the shared genetics for 740 LTC-pairs (30% of all pairs considered). For a further 161 LTC-pairs, the genetic similarity between the LTCs was entirely accounted for by BMI genetics. This list included diabetes and osteoarthritis: , as well as those involving LTCs from the same broad family, or ‘domain’, such as gout and osteoarthritis: . Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset of these pairs, and therefore BMI-lowering interventions would reduce the prevalence of these pairs of LTCs. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently have both LTCs. Conclusions: Our genetics-centred approach shows that obesity is an important mechanistic cause of many shared long-term conditions. We identify LTC pairs for which obesity is the predominating shared risk factor, and cases where it is one of the several shared risk factors involved. Our method for calculating full and partial genetic correlations is published as an R package {partialLDSC} for use by the research community.
- Open Access
- 5 June 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (9) , 1817-1827
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach
Aims/hypothesis: Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis. Methods: Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013–2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified: n=66,810, DPP4i n=76,172), ≥70 years (SGLT2i n=10,419, DPP4i n=33,434). Outcomes were assessed using the instrumental variable causal inference method and prescriber preference as the instrument. Results: Risk of diabetic ketoacidosis was increased with SGLT2i in those aged ≥70 (incidence rate ratio compared with DPP4i: 3.82 [95% CI 1.12, 13.03]), but not in those aged 1c reduction was similar between SGLT2i and DPP4i (−0.3 mmol/mol [−1.6, 1.1], −0.02% [0.1, 0.1]), but in those <70, SGLT2i were more effective (−4 mmol/mol [4.8, −3.1], −0.4% [−0.4, −0.3]). Conclusions/interpretation: Causal analysis suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes. Graphical
- 5 June 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (9) , 1817-1827
Open AccessSafety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach
Aims/hypothesis: Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis. Methods: Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013–2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified: n=66,810, DPP4i n=76,172), ≥70 years (SGLT2i n=10,419, DPP4i n=33,434). Outcomes were assessed using the instrumental variable causal inference method and prescriber preference as the instrument. Results: Risk of diabetic ketoacidosis was increased with SGLT2i in those aged ≥70 (incidence rate ratio compared with DPP4i: 3.82 [95% CI 1.12, 13.03]), but not in those aged 1c reduction was similar between SGLT2i and DPP4i (−0.3 mmol/mol [−1.6, 1.1], −0.02% [0.1, 0.1]), but in those <70, SGLT2i were more effective (−4 mmol/mol [4.8, −3.1], −0.4% [−0.4, −0.3]). Conclusions/interpretation: Causal analysis suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes. Graphical
- Open Access
- 17 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4426
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients
The solute carrier organic anion transporter family member 1B1 (SLCO1B1) encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in SLCO1B1, such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and rare SLCO1B1 variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records. We studied 51 predicted gain/loss-of-function variants affecting OATP1B1. Both SLCO1B1*5 alone and the SLCO1B1*15 haplotype increased LDL during treatment (beta*5 = 0.08 mmol/L, p = 6 × 10−8; beta*15 = 0.03 mmol/L, p = 3 × 10−4), as did the likelihood of discontinuing statin prescriptions (hazard ratio*5 = 1.12, p = 0.04; HR*15 = 1.05, p = 0.04). SLCO1B1*15 and SLCO1B1*20 increased the risk of General Practice (GP)-diagnosed muscle symptoms (HR*15 = 1.22, p = 0.003; HR*20 = 1.25, p = 0.01). We estimated that genotype-guided prescribing could potentially prevent 18% and 10% of GP-diagnosed muscle symptoms experienced by statin patients, with *15 and *20, respectively. The remaining common variants were not individually significant. Rare variants in SLCO1B1 increased LDL in statin users by up to 1.05 mmol/L, but replication is needed. We conclude that genotype-guided treatment could reduce GP-diagnosed muscle symptoms in statin patients; incorporating further SLCO1B1 variants into clinical prediction scores could improve LDL control and decrease adverse events, including discontinuation.
- 17 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4426
Open AccessSLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients
The solute carrier organic anion transporter family member 1B1 (SLCO1B1) encodes the organic anion-transporting polypeptide 1B1 (OATP1B1 protein) that transports statins to liver cells. Common genetic variants in SLCO1B1, such as *5, cause altered systemic exposure to statins and therefore affect statin outcomes, with potential pharmacogenetic applications; yet, evidence is inconclusive. We studied common and rare SLCO1B1 variants in up to 64,000 patients from UK Biobank prescribed simvastatin or atorvastatin, combining whole-exome sequencing data with up to 25-year routine clinical records. We studied 51 predicted gain/loss-of-function variants affecting OATP1B1. Both SLCO1B1*5 alone and the SLCO1B1*15 haplotype increased LDL during treatment (beta*5 = 0.08 mmol/L, p = 6 × 10−8; beta*15 = 0.03 mmol/L, p = 3 × 10−4), as did the likelihood of discontinuing statin prescriptions (hazard ratio*5 = 1.12, p = 0.04; HR*15 = 1.05, p = 0.04). SLCO1B1*15 and SLCO1B1*20 increased the risk of General Practice (GP)-diagnosed muscle symptoms (HR*15 = 1.22, p = 0.003; HR*20 = 1.25, p = 0.01). We estimated that genotype-guided prescribing could potentially prevent 18% and 10% of GP-diagnosed muscle symptoms experienced by statin patients, with *15 and *20, respectively. The remaining common variants were not individually significant. Rare variants in SLCO1B1 increased LDL in statin users by up to 1.05 mmol/L, but replication is needed. We conclude that genotype-guided treatment could reduce GP-diagnosed muscle symptoms in statin patients; incorporating further SLCO1B1 variants into clinical prediction scores could improve LDL control and decrease adverse events, including discontinuation.